Immunoglobulin G1 [143-aspartic acid,236-glutamic acid], anti-(human cytotoxic T-lymphocyte-associated protein 4) (human monoclonal HBM4003 heavy chain V-D-J region) fusion protein with immunoglobulin G1 (human ?1-chain C region), dimer
Neuroendocrine Tumors
Harbour BioMed (Guangzhou) Co. Ltd.monoclonal_antibodyPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 73/ 100
Competitive context
61 Active assets in the Neuroendocrine Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM ITM Solucin GmbH | Phase 3 | BB |
Irinotecan First Affiliated Hospital Xi'an Jiaotong University | Phase 4 | BB |
Eloxatin ITM Solucin GmbH | Phase 3 | BB |
Bms-907351 Fox Chase Cancer Center | Phase 3 | BB |
Pasireotide RECORDATI GROUP | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Immunoglobulin G1 [143-aspartic acid,236-glutamic acid], anti-(human cytotoxic T-lymphocyte-associated protein 4) (human monoclonal HBM4003 heavy chain V-D-J region) fusion protein with immunoglobulin G1 (human ?1-chain C region), dimer is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →